Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Nine Months Ended

September 30,

2008 2007

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income (loss) $210,962 $(235,886)

Adjustments to reconcile net

income to net cash provided by

operating activities:

Deferred income tax

(benefit) expense (9,409) 8,750

Shortfall tax benefits from

stock-based compensation (451) (222)

Depreciation and amortization 128,772 101,206

Stock-based compensation expense 32,543 34,940

Gain on sale of investment - (5,791)

Gain on forgiveness of debt - (5,319)

Loss on disposals of property

and equipment 2,740 2,873

Impairment charges 1,164 -

Other (396) 180

Changes in operating

assets and liabilities:

Receivables (74,258) (26,218)

Inventory (14,557) (1,881)

Other assets (99,008) (28,552)

Accounts payable and

accrued expenses 34,526 380,776

Other liabilities 70,
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/20/2014)... 20, 2014 The report “Pharmacy ... Systems, Packaging and Labeling Systems, Table-top Counters) by ... Global Forecasts & Trends to 2019” analyzes and ... in North America, Europe, Asia-Pacific, and the Rest ... tables and 30 figures spread through 300 pages ...
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
(Date:10/20/2014)... OncLive® is pleased ... at Thomas Jefferson University has joined its Strategic ... Alliance Partnership program, the Sidney Kimmel Cancer Center ... awareness of the Center’s cutting-edge research programs, comprehensive ... and other health care professionals from the Sidney ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... from Product Sales Increased 149% to $3.5 Million - ... - Gross Profit ... AMDL, Inc. (Amex: ADL ),is a vertically integrated ... Jiangxi and Jilin,China. Through its wholly owned subsidiary Jade Pharmaceutical ...
... scatter and channel light, University of California, San ... junction solar cells with the potential for nearly ... Diego effort to break the theoretical limit of ... recently received a big funding boost from the ...
... 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX:,MS), a leading ... financial and operational results for the first quarter ended,March ... Company, is,developing dirucotide (also known as MBP8298), a synthetic ... in Canada, Europe and the US., "During the ...
Cached Biology Technology:AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 2AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 3UC San Diego nanostructures will raise thin-film solar cell efficiency 2BioMS Medical announces first quarter 2008 results 2BioMS Medical announces first quarter 2008 results 3BioMS Medical announces first quarter 2008 results 4BioMS Medical announces first quarter 2008 results 5
(Date:10/16/2014)... can be cultivated efficiently, they are anything but ... by monoculture cultivation is becoming increasingly evident. Despite ... form and are regarded as the sole possibility ... quite wrongfully, finds Bernhard Schmid, an ecology professor ... novel form of agriculture and forestry. After all, ...
(Date:10/15/2014)... PORT WASHINGTON, N.Y. , Oct. 15, 2014 ... in technology solutions for home and community-based care, ... the benefits of implementing Sandata,s Santrax® Electronic Visit ... Quality Care Services is a home health company ... Texas . ...
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... PA, January 15, 2013 A new study has ... counteract some pathologic features in a mouse model of ... known to produce long-term improvement of the symptoms in ... characterized by progressive muscle wasting, respiratory and cardiac impairments, ...
... should sharpen their ability to spot environmental conditions that ... having a certain abundance of fish assures how much ... harvest of fish is only closely linked to abundance ... a University of Washington-led study, according to Ray Hilborn, ...
... A research team involving several scientists from the University ... in the devastating pine beetle outbreaks ravaging the West: ... streams as scientists had previously believed. According to ... shows that smaller trees and other vegetation that survive ...
Cached Biology News:Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy 2Potential harvest of most fish stocks largely unrelated to abundance 2Potential harvest of most fish stocks largely unrelated to abundance 3CU-led study shows pine beetle outbreak buffers watersheds from nitrate pollution 2CU-led study shows pine beetle outbreak buffers watersheds from nitrate pollution 3
Request Info...
Request Info...
... Art GLP facility with capabilities from ... fermentation. Coordinated process development from ... operation capable of simultaneous production runs ... Hosts include: Bacteria, Yeast, Fungi, ...
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
Biology Products: